Loading stock data…
CCCC
$2.92+0.09 (+3.18%)
Market ClosedLast close May 1
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
C4 Therapeutics, Inc. in the Healthcare sector is trading at $2.92. The stock is currently 24% below its 52-week high of $3.82, remaining 19.2% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why CCCC maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.92
Potential Upside
5%
Whystock Fair Value$3.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$290.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.92%
Volume
Today's trading volume
4.84M
Recent News
Assessing Roche Holding (SWX:ROG) Valuation After New C4 Therapeutics Oncology Partnership
Roche Holding (SWX:ROG) shares are in focus after C4 Therapeutics announced a new collaboration to develop degrader antibody conjugates for oncology, combining targeted protein degradation with antibody drug conjugation. See our latest analysis for Roche Holding. Roche Holding's share price has softened recently, with a 1 month share price return of 10.47% and a 7 day share price return of 3.04%. However, the 1 year total shareholder return stands at 10.30%, which hints that long term...
Roche’s DAC investment; Big Pharma’s lavish CEO bumps
Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.
Roche Explores Degrader Antibody Conjugates To Support Oncology Pipeline
Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates for cancer treatment. The partnership combines targeted protein degradation with antibody drug conjugation to explore new oncology drug modalities. Roche receives exclusive rights to selected oncology targets, with the agreement including milestone payments and royalties. Roche Holding, trading at around CHF315.6, has a strong oncology franchise and is now adding a fresh...
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.